Key result
The CHA2DS2-VA score had a non-statistically significant difference compared to the CHA2DS2-VASc score for predicting ischemic stroke or systemic embolism (C-statistic 0.647 vs 0.655, p=0.258).
Why the study?
Given limited data in non-Western cohorts, the objective was to compare the performance of CHA2DS2-VASc and CHA2DS2-VA scores for predicting ischemic stroke/systemic embolism in an Asian AF population.
Does the CHA2DS2-VA score perform similarly to the CHA2DS2-VASc score for predicting ischemic stroke or systemic embolism in Asian patients with atrial fibrillation?
Cohort (n=3,405)
Yes
Does the CHA2DS2-VA score perform similarly to the CHA2DS2-VASc score for predicting ischemic stroke or systemic embolism in Asian patients with atrial fibrillation?
Effect estimate: C-statistic 0.647 vs 0.655
p-value: p=0.258
The CHA2DS2-VA score performs similarly to the CHA2DS2-VASc score for predicting ischemic stroke and systemic embolism in Asian patients with atrial fibrillation.
CHA2DS2-VA shows similar predictive ability to CHA2DS2-VASc in Asian AF; leaves open whether it can supplant the sex-inclusive score in guidelines.
Background The CHA 2 DS 2 -VA score, derived by the removal of female sex from the CHA 2 DS 2 -VASc score, has recently been recommended for the prediction of ischemic stroke/systemic embolism (SSE) in patients with atrial fibrillation (AF). Objective Given the limited data in non-Western cohorts, the objective was to compare the performance of CHA 2 DS 2 -VASc and CHA 2 DS 2 -VA score for the prediction of SSE in an Asian population. Methods AF patients from the prospective multicentre COOL-AF registry were studied. Patients were followed-up every 6 months for 3 years. The primary outcome was SSE. C-statistics were used to compare the performance of CHA 2 DS 2 -VASc and CHA 2 DS 2 -VA scores for SSE risk prediction. The pattern of OAC use is according to the practicing physicians. Results A total of 3405 patients were studied (mean age 67.8±11.3 years, 41.8% female). The incidence rate of SSE was 1.51 (1.26-1.78) per 100 person-years. The risk ratio for SSE for females was higher than males at CHA 2 DS 2 -VA scores ≥2 [1.72 (1.19-2.50), p=0.004], similar for patients with and without OAC use. The C-statistics for SSE was not statistically significantly different between CHA 2 DS 2 -VASc and CHA 2 DS 2 -VA scores [0.655 (0.639-0.671) and 0.647 (0.631-0.663), p=0.258]. Females had a greater risk of SSE compared to males at age above 70 years (p-value interaction 0.007). Conclusion Female patients with AF have an increased SSE risk compared to male patients with a higher CHA 2 DS 2 -VA scores and at age above 70 years. The CHA 2 DS 2 -VA scores had a numerical but non-statistically significant difference to CHA 2 DS 2 -VASc score for SSE risk prediction.
No takes yet. Share an insight, caveat, or question.
Krittayaphong et al. (2025) conducted a cohort in atrial fibrillation (n=3,405). CHA2DS2-VA score vs. CHA2DS2-VASc score was evaluated on ischemic stroke/systemic embolism (SSE) (C-statistic 0.647 vs 0.655, p=0.258). The CHA2DS2-VA score had a non-statistically significant difference compared to the CHA2DS2-VASc score for predicting ischemic stroke or systemic embolism (C-statistic 0.647 vs 0.655, p=0.258).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: